Insider · CIK 0001601121
Robert G. Shawah
Files at ACXP (Acurx Pharmaceuticals, Inc.). First filing -, latest -.
In brief
Robert G. Shawah files SEC Form 4 as CFO at ACXP (Acurx Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Robert G. Shawah has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | ACXP Acurx Pharmaceuticals, Inc. | AGrant or award Stock Optionderivative | +25,900 | $0.00 | $0 | 25,900 | Apr 22, 2026 |
| Feb 5, 2025 | ACXP Acurx Pharmaceuticals, Inc. | AGrant or award Stock Optionderivative | +145,500 | $0.00 | $0 | 145,500 | Feb 6, 2025 |
Questions about Robert G. Shawah
Answered from the filings on this page, as of the latest one.
Is Robert G. Shawah buying or selling?
Robert G. Shawah has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Robert G. Shawah's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Robert G. Shawah has 0.
Where does Robert G. Shawah file Form 4?
Robert G. Shawah has filed Form 4 at ACXP (Acurx Pharmaceuticals, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.